U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389642) titled 'Brain Oligometastasis in NSCLC' on Jan. 28.
Brief Summary: 75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonie Institute
Study Start Date: Jan. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Brain Oligometastatic
Non-small Cell Lung Cancer
Intervention:
OTHER: Stand...